San Diego-based Lpath, Inc. recently reported that its experimental drug Asonep failed to meet its primary endpoint in a mid-stage trial in patients with the most common form of kidney cancer. The company said that its Phase IIa study of Asonep did not meet the primary endpoint of a statistically …